Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zai Lab Doses First Patient in China Trial of PD-1 for NSCLC

publication date: Oct 8, 2020

Zai Lab of Shanghai has dosed the first patient in a China Phase III trial of retifanlimab, an anti-PD-1 antibody, as a first line treatment for metastatic non-small-cell-lung cancer (NSCLC). In 2019, Zai in-licensed China rights to the candidate from Incyte in a $77.5 million agreement. Zai will be in charge of the China arm of Incyte's global Phase III trial of retifanlimab, which will be administered in combination with platinum-based chemotherapy. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021